The Role Of Long Non-coding RNA Linc00152 In Oxaliplatin Resistance Of Colorectal Cancer

Long non-coding RNAs(LncRNAs) act as crucial regulators in plenty of human cancers,yet their potential roles and molecular mechanisms in chemoresistance are poorly understood.Our present study showed that a novel lncRNA,Linc00152(long intergenic non-coding RNA 152),promoted tumor progression and conferred resistance to oxaliplatin(L-OHP)-induced apoptosis in vitro and in vivo.It antagonized chemosensitivity through acting as a competing endogenous RNA(ceRNA) to modulate the expression of mi R-193a-3p,and then ERBB4.Knockdown of ERBB4 in colorectal cancer cells decreased AKT phosphorylation,which resulted in decreased L-OHP resistance.Consistent with above findings,the specific AKT signaling inhibitor and activator were used,respectively,which demonstrated that Linc00152 contributed to L-OHP resistance at least partly through activating AKT pathway.Further studies indicated that Linc00152 was increased and appeared to be an independent prognostic factor for decreased survival and increased disease recurrence in stage ? and ? colorectal cancer patients undergoing L-OHP-based chemotherapy after surgery.Collectively,our findings established Linc00152 as a candidate prognostic indicator of outcome and drug responsiveness in colorectal cancer patients,and the involvement of ceRNAs mechanism in Linc00152/mi R-193a-3p/ERBB4/AKT signaling axis may provide a novel choice in the investigation of drug resistance.